Concepedia

Publication | Open Access

Capsid Inhibition with Lenacapavir in Multidrug-Resistant HIV-1 Infection

270

Citations

10

References

2022

Year

Abstract

In patients with multidrug-resistant HIV-1 infection, those who received lenacapavir had a greater reduction from baseline in viral load than those who received placebo. (Funded by Gilead Sciences; CAPELLA ClinicalTrials.gov number, NCT04150068.).

References

YearCitations

Page 1